SNPX vs. KTRA, CING, KZIA, CPHI, PTIX, SONN, GNPX, NEXI, YMTX, and DRUG
Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Kintara Therapeutics (KTRA), Cingulate (CING), Kazia Therapeutics (KZIA), China Pharma (CPHI), Protagenic Therapeutics (PTIX), Sonnet BioTherapeutics (SONN), Genprex (GNPX), NexImmune (NEXI), Yumanity Therapeutics (YMTX), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical preparations" industry.
Kintara Therapeutics (NASDAQ:KTRA) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
Synaptogenix is trading at a lower price-to-earnings ratio than Kintara Therapeutics, indicating that it is currently the more affordable of the two stocks.
0.6% of Kintara Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 4.3% of Kintara Therapeutics shares are owned by insiders. Comparatively, 4.3% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Synaptogenix's return on equity of 0.00% beat Kintara Therapeutics' return on equity.
Kintara Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Kintara Therapeutics received 15 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 88.89% of users gave Kintara Therapeutics an outperform vote while only 50.00% of users gave Synaptogenix an outperform vote.
In the previous week, Kintara Therapeutics had 2 more articles in the media than Synaptogenix. MarketBeat recorded 4 mentions for Kintara Therapeutics and 2 mentions for Synaptogenix. Kintara Therapeutics' average media sentiment score of 1.47 beat Synaptogenix's score of 0.45 indicating that Synaptogenix is being referred to more favorably in the news media.
Summary
Kintara Therapeutics beats Synaptogenix on 7 of the 13 factors compared between the two stocks.
Get Synaptogenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synaptogenix Competitors List
Related Companies and Tools
